- Home
- CGNT vs PRAX Comparison
CGNT vs PRAX Comparison
Compare CGNT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- PRAX
- Stock Information
- Founded
- CGNT 2020
- PRAX 2015
- Country
- CGNT Israel
- PRAX United States
- Employees
- CGNT N/A
- PRAX N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- PRAX Health Care
- Exchange
- CGNT Nasdaq
- PRAX Nasdaq
- Market Cap
- CGNT 743.4M
- PRAX 646.2M
- IPO Year
- CGNT N/A
- PRAX 2020
- Fundamental
- Price
- CGNT $9.29
- PRAX $28.47
- Analyst Decision
- CGNT Hold
- PRAX Strong Buy
- Analyst Count
- CGNT 3
- PRAX 9
- Target Price
- CGNT $8.25
- PRAX $123.33
- AVG Volume (30 Days)
- CGNT 540.4K
- PRAX 538.4K
- Earning Date
- CGNT 04-02-2025
- PRAX 05-12-2025
- Dividend Yield
- CGNT N/A
- PRAX N/A
- EPS Growth
- CGNT N/A
- PRAX N/A
- EPS
- CGNT N/A
- PRAX N/A
- Revenue
- CGNT $350,632,000.00
- PRAX $8,553,000.00
- Revenue This Year
- CGNT $8.64
- PRAX N/A
- Revenue Next Year
- CGNT $9.76
- PRAX $789.73
- P/E Ratio
- CGNT N/A
- PRAX N/A
- Revenue Growth
- CGNT 11.88
- PRAX 249.53
- 52 Week Low
- CGNT $6.21
- PRAX $26.70
- 52 Week High
- CGNT $11.12
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- CGNT 56.45
- PRAX 29.18
- Support Level
- CGNT $8.45
- PRAX $26.70
- Resistance Level
- CGNT $10.32
- PRAX $37.91
- Average True Range (ATR)
- CGNT 0.54
- PRAX 3.32
- MACD
- CGNT 0.13
- PRAX 0.32
- Stochastic Oscillator
- CGNT 61.68
- PRAX 13.72
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.